Actinium Pharmaceuticals, Inc. quarterly report, Q3 FY2009

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2009, for Cactus Ventures, Inc. (Note: The input metadata referenced "Actinium Pharmaceuticals," but the filing text explicitly identifies the registrant as Cactus Ventures, Inc.). The company is a Nevada corporation classified as a shell company and a smaller reporting company. It has no active operations, no employees, and is currently seeking a merger or acquisition target to become a public reporting entity.

Key Financial Metrics

MetricPeriod Ended Sep 30, 2009Period Ended Sep 30, 2008
Revenue$0$0
Net Loss$(12,834)$(23,631)
Operating Expenses$8,221$20,103
Interest Expense$4,613$3,528
Cash and Cash Equivalents$2,146$2,218
Total Assets$2,146$2,218
Total Liabilities$88,940$76,179
Shareholders' Deficit$(86,794)$(73,961)
Working Capital$(21,405)$(24,134)
Notes Payable (Related Parties)$65,389$49,827

Material Changes vs. Prior Period

  • Reduced Net Loss: The net loss for the nine months ended September 30, 2009, decreased to $12,834 from $23,631 in the prior year period, primarily due to a significant reduction in operating expenses.
  • Expense Reduction: Total operating expenses dropped from $20,103 to $8,221. This was driven by a decrease in "Other costs" (from $7,191 to $634) and "Professional fees" (from $12,840 to $7,515).
  • Increased Debt: Notes payable to related parties increased by $15,562 to $65,389, reflecting new borrowings for working capital.
  • Accrued Liabilities: Accrued interest increased by $4,613 to $13,115, while accrued legal fees decreased significantly from $5,490 to $570.

Outlook, Risks, and Management Commentary

  • Going Concern: The filing explicitly states that the company's net loss, negative working capital, and stockholders' deficit raise substantial doubt about its ability to continue as a going concern. Continuation is dependent on raising additional funds and implementing a business plan.
  • Business Plan: The company has no specific business plan other than searching for a merger or acquisition target. It anticipates expenses of approximately $20,000 for the next 12 months.
  • Liquidity: Management anticipates meeting future needs through advances from the president, though no assurances are given. The company has no lines of credit or other assets.
  • Risks: Risks include the inability to locate a suitable target company, failure to consummate a merger, and significant dilution to existing shareholders upon any future acquisition.

Investor Verification Checklist

  • Identity Discrepancy: Verify the correct registrant name (Cactus Ventures, Inc.) versus the metadata provided (Actinium Pharmaceuticals, Inc.).
  • Shell Status: Confirm the company has no revenue, no employees, and is solely seeking a reverse merger or acquisition.
  • Related Party Debt: Review the $65,389 in notes payable to related parties and the terms of repayment.
  • Going Concern Risk: Assess the likelihood of the company raising capital given the $2,146 cash balance and $88,940 in liabilities.
  • Share Count: Note the 11,155,008 shares of common stock outstanding, which may be subject to significant dilution in a future transaction.